📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
CRISIL Assigns 'A/Stable' Rating to CPPLUS Subsidiary's Rs 325 Cr Bank Facilities
CRISIL Ratings has assigned a long-term rating of 'CRISIL A/Stable' and a short-term rating of 'CRISIL A1' to the bank loan facilities of AIL Dixon Technologies Private Limited. This entity is a material wholly-owned subsidiary of Aditya Infotech Limited (CPPLUS). The total bank loan facilities covered under this rating amount to Rs. 325 Crore. This assignment provides a benchmark for the subsidiary's creditworthiness and its ability to service debt obligations efficiently.
Key Highlights
CRISIL assigned a long-term rating of 'CRISIL A/Stable' for bank facilities.
CRISIL assigned a short-term rating of 'CRISIL A1' for bank facilities.
Total bank loan facilities rated amount to Rs. 325 Crore.
Ratings assigned to AIL Dixon Technologies Private Limited, a material wholly-owned subsidiary.
💼 Action for Investors
Investors should take this as a positive sign of the subsidiary's financial stability and the group's ability to leverage its balance sheet for growth. No immediate action is required, but the 'Stable' outlook suggests consistent performance is expected.
Loading analysis...
Piramal Pharma Approves FY26 Results; Re-appoints Nandini Piramal as Chairperson for 3 Years
Piramal Pharma's Board has approved the audited financial results for FY26 with an unmodified auditor's opinion. Key leadership continuity was secured through the re-appointment of Ms. Nandini Piramal as Chairperson and Mr. Peter DeYoung as Executive Director for three-year terms. The board also re-appointed two Independent Directors for five-year terms and appointed a new Company Secretary. These moves ensure stability in governance and strategic oversight for the upcoming years.
Key Highlights
Audited FY26 financial results approved with an unmodified opinion from Statutory Auditors.
Nandini Piramal re-appointed as Chairperson for 3 years starting April 1, 2027.
Peter DeYoung re-appointed as Executive Director for 3 years starting October 6, 2026.
Maneesh Sharma appointed as Company Secretary and Compliance Officer effective April 29, 2026.
Registered office address changed within Mumbai effective April 30, 2026.
💼 Action for Investors
Investors should maintain their positions as leadership continuity provides stability. Focus on the specific FY26 profit and revenue growth figures in the detailed report to assess fundamental performance.
Loading analysis...
Piramal Pharma Q4FY26: Revenue Flat at ₹2,752 Cr, FY26 EBITDA Drops 28% Amid Impairment Loss
Piramal Pharma reported flat Q4FY26 revenue of ₹2,752 Cr and a 3% decline in annual revenue to ₹8,869 Cr, primarily due to inventory destocking in the CDMO segment. The company recorded a consolidated net loss of ₹326 Cr for FY26, weighed down by a ₹176 Cr impairment charge on intangible assets under development. While the CDMO business struggled with a 10% annual revenue drop, the Consumer Healthcare division grew 17% with strong e-commerce traction. Management expects a recovery in FY27 driven by improved biopharma funding and new product acquisitions like Kenalog.
Key Highlights
FY26 EBITDA margins contracted to 13% from 17% in FY25, with absolute EBITDA falling 28% to ₹1,135 Cr.
Recognized a one-time impairment loss of ₹176 Cr in Q4FY26 due to reassessed commercial viability of certain intangible assets.
Consumer Healthcare (PCH) power brands grew 24% YoY, now contributing 52% of segment sales with e-commerce growing at 48%.
CDMO segment saw a 75% YoY increase in US biopharma funding in H2FY26, leading to a healthy pick-up in order inflows.
Net Debt remained stable at ₹4,140 Cr, while the company invested US$94Mn in Capex during FY26.
💼 Action for Investors
Investors should monitor the recovery in the CDMO order book and margin improvement in FY27 as management expects a turnaround. The stock may face short-term pressure due to the significant annual loss and margin contraction.
Loading analysis...
Piramal Pharma Re-appoints Top Leadership and Approves FY26 Audited Financial Results
Piramal Pharma's Board has approved the audited financial results for the quarter and fiscal year ended March 31, 2026, with an unmodified audit opinion. The company ensured leadership stability by re-appointing Chairperson Nandini Piramal and CEO Peter DeYoung for three-year terms starting in 2027 and 2026, respectively. Additionally, Maneesh Sharma has been appointed as the new Company Secretary and Compliance Officer effective April 29, 2026. The board also extended the terms of two Independent Directors for five years each, starting in March 2027.
Key Highlights
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Re-appointed Ms. Nandini Piramal as Chairperson for a 3-year term effective April 1, 2027.
Re-appointed Mr. Peter DeYoung as Executive Director for a 3-year term effective October 6, 2026.
Appointed Mr. Maneesh Sharma as Company Secretary and KMP effective April 29, 2026, following the cessation of the interim officer.
Re-appointed Independent Directors Sridhar Gorthi and Peter Stevenson for second 5-year terms starting March 2027.
💼 Action for Investors
Investors should take confidence in the leadership continuity and the clean audit report. Focus on the detailed financial performance metrics in the FY26 results to assess the company's growth trajectory.
Loading analysis...
Piramal Pharma Approves FY26 Results and Re-appoints Key Leadership for 3-5 Year Terms
Piramal Pharma's board has approved the audited financial results for the fiscal year ended March 31, 2026, with an unmodified audit opinion. The company ensured leadership stability by re-appointing Chairperson Nandini Piramal and Executive Director Peter DeYoung for three-year terms starting in 2027 and 2026, respectively. Furthermore, two independent directors were re-appointed for five-year terms, and a new Company Secretary was appointed. The board also authorized a change in the company's registered office address within Mumbai effective April 30, 2026.
Key Highlights
Approved audited standalone and consolidated financial results for FY26 with an unmodified auditor's opinion.
Re-appointed Ms. Nandini Piramal as Chairperson for a 3-year term effective April 1, 2027.
Re-appointed Mr. Peter DeYoung as Executive Director for a 3-year term effective October 6, 2026.
Extended terms for Independent Directors Sridhar Gorthi and Peter Stevenson for 5 years each starting March 2027.
Appointed Mr. Maneesh Sharma as Company Secretary and Compliance Officer effective April 29, 2026.
💼 Action for Investors
Investors should review the detailed FY26 financial statements to assess the company's operational performance. The continuity in top management and the board is a positive sign for long-term strategic stability.
Loading analysis...
Aditya Infotech (CPPLUS) Signs 50:50 Joint Venture Agreement with Orient Cables
Aditya Infotech Limited (CPPLUS) has executed a definitive 50:50 Joint Venture agreement with Orient Cables (India) Limited to manufacture electric cables, including LAN and CCTV cables. This strategic move follows an earlier MoU signed in February 2026 and aims to facilitate backward integration for the company's security products. The JV company will be an associate of Aditya Infotech, with equal board representation and joint control over operations. This arrangement is expected to secure the supply chain, improve cost efficiencies, and enhance quality control for CPPLUS's core business.
Key Highlights
Execution of a 50:50 Joint Venture agreement with Orient Cables (India) Limited on April 16, 2026
Focus on manufacturing LAN cables, CCTV cables, connectors, and terminated assemblies
Strategic backward integration to ensure reliable supply and enhance operational effectiveness
JV Company will supply products to both Aditya Infotech and Orient Cables for further sale
Governance structure includes equal board representation and mutual approval for critical matters
💼 Action for Investors
Investors should view this as a positive long-term strategic move for supply chain stability and potential margin improvement through backward integration. Monitor the timeline for the commencement of manufacturing operations at the JV facility.
Loading analysis...
Piramal Pharma Receives US FDA EIR for Lexington Facility; Inspection Successfully Closed
Piramal Pharma Limited has received an Establishment Inspection Report (EIR) from the US FDA for its manufacturing facility located in Lexington, Kentucky, USA. The inspection, which was previously reported in December 2025, has been classified as Voluntary Action Indicated (VAI). This classification signifies the successful closure of the regulatory audit, ensuring the facility meets US compliance standards. The clearance is a positive development for the company's contract development and manufacturing operations in the US market.
Key Highlights
US FDA issued an Establishment Inspection Report (EIR) for the Lexington, USA manufacturing site.
The inspection status is classified as Voluntary Action Indicated (VAI), marking a successful closure.
The audit was originally initiated and disclosed on December 11, 2025.
Successful clearance ensures uninterrupted operations and compliance for products manufactured at this facility for the US market.
💼 Action for Investors
This regulatory clearance removes a potential overhang on the stock and validates the company's quality systems. Investors should view this as a positive signal for the company's US-based manufacturing capabilities.
Loading analysis...
CRISIL Assigns 'A/Stable' Rating to Aditya Infotech's Rs 555 Cr Bank Facilities
Aditya Infotech Limited, known for the CPPLUS brand, has been assigned a 'CRISIL A/Stable' credit rating for its bank loan facilities totaling Rs 555 Crore. This rating assignment follows the revocation of a previous suspension by CRISIL, indicating a return to active monitoring and improved transparency. Concurrently, the company has withdrawn its previous rating of 'CARE BBB+; Stable' from CARE Ratings. The shift to an 'A' category rating from CRISIL represents a significant improvement in the company's perceived creditworthiness and financial stability.
Key Highlights
CRISIL assigned a Long Term Rating of 'CRISIL A/Stable' for bank loan facilities worth Rs 555 Crore.
The rating assignment follows the revocation of a previous suspension by CRISIL Ratings.
The company has officially withdrawn its previous 'CARE BBB+; Stable' rating from CARE Ratings.
The transition to an 'A' rating signifies a stronger credit profile compared to the previous 'BBB+' investment grade.
💼 Action for Investors
Investors should view this credit rating upgrade as a positive signal of the company's strengthening balance sheet and reduced default risk. This improved rating may help the company negotiate better interest rates on future borrowings, potentially improving net margins.
Loading analysis...
Piramal Pharma Completes Acquisition of Kenalog® Branded Injectable from Bristol-Myers Squibb
Piramal Pharma's subsidiary, Piramal Critical Care B.V., has successfully completed the acquisition of the Kenalog® brand and associated products from Bristol-Myers Squibb. This strategic move is aimed at strengthening the company's Complex Hospital Generics portfolio, which is a high-margin segment. The acquisition enhances Piramal's market presence across the United States, Europe, and the Asia Pacific region. This completion follows the initial agreement announced in January 2026, marking a significant milestone in the company's inorganic growth strategy.
Key Highlights
Successful completion of Kenalog® brand acquisition from Bristol-Myers Squibb (BMS).
Acquisition executed via Piramal Critical Care B.V., a step-down wholly owned subsidiary.
Strengthens the 'Complex Hospital Generics' portfolio across global markets.
Expands operational footprint in key geographies including the US, Europe, and Asia Pacific.
Follows through on the initial disclosure made on January 28, 2026.
💼 Action for Investors
Investors should look for improved margins in the Critical Care segment as branded products typically offer better pricing power. Monitor upcoming quarterly earnings for the first full-quarter contribution of Kenalog® to the top line.
Loading analysis...
Aditya Infotech Shareholders Approve ESOP 2024 and Director Remuneration Revisions
Aditya Infotech Limited (CPPLUS) has successfully passed six special resolutions via postal ballot with a total voter turnout of 90.14%. Key approvals include the ratification of the Employee Stock Option Plan (ESOP) 2024 and its extension to employees of subsidiary and group companies. Shareholders also approved remuneration revisions for the Chairman, Managing Director, and Whole-Time Director. Notably, while resolutions passed with over 93% overall support, public non-institutional investors showed significant dissent, voting over 98% against the ESOP and MD remuneration proposals.
Key Highlights
Ratification of Aditya Infotech ESOP Plan 2024 approved with 93.33% majority.
Remuneration revision for Chairman Hari Shanker Khemka received the highest support at 99.56%.
Extension of ESOP benefits to group and subsidiary employees passed with 93.33% of votes in favour.
Significant retail dissent noted with public non-institutional investors voting 98.36% against the ESOP ratification.
Total votes polled represented 10,61,85,572 shares out of 11,77,98,084 total outstanding shares.
💼 Action for Investors
Investors should monitor the potential equity dilution from the new ESOP plan and ensure that the revised management remuneration remains aligned with the company's long-term profit growth. The high level of retail investor dissent on specific resolutions warrants a closer look at the company's governance communication.
Loading analysis...
Rajshree Polypack Clarifies Identical Standalone & Consolidated Q2 FY26 Results
Rajshree Polypack Limited (RPPL) responded to NSE's clarification request regarding identical standalone and consolidated financial figures for the quarter ended September 30, 2025. The company explained that its sole joint venture, Olive Ecopak Private Limited, has accumulated losses exceeding RPPL's investment, resulting in a carrying value of zero under Ind AS 28. Consequently, no further losses are recognized in the consolidated statement, making it identical to the standalone results. For Q2 FY26, the company reported a total income of ₹8,837.07 Lakhs and a net profit of ₹459.51 Lakhs.
Key Highlights
Q2 FY26 Revenue from Operations stood at ₹8,642.85 Lakhs, up from ₹8,251.65 Lakhs in the previous quarter.
Net Profit for the quarter was ₹459.51 Lakhs with a Basic EPS of ₹0.62.
Identical standalone and consolidated figures occur because the JV investment value is nil due to accumulated losses.
A revision in the useful life of machinery from 15 to 20-25 years reduced depreciation by ₹147.06 Lakhs for the half-year.
The company converted 1,50,000 share warrants into 9,00,000 equity shares following a stock split.
💼 Action for Investors
Investors should recognize that the identical reporting is a technical accounting outcome of JV losses and not a reporting error. Monitor the impact of revised depreciation on long-term margins and the eventual turnaround of the Olive Ecopak joint venture.
Loading analysis...
Aditya Infotech Seeks Approval for ESOP 2024 Ratification and Director Remuneration Revisions
Aditya Infotech Limited (CPPLUS) has issued a postal ballot notice seeking shareholder approval for the ratification of its Employee Stock Option Plan 2024. The company also proposes extending ESOP benefits to employees of subsidiary, associate, and holding companies to align group-wide interests. Furthermore, the ballot includes special resolutions to revise the remuneration packages for three key directors: Hari Shanker Khemka, Aditya Khemka, and Ananmay Khemka. The e-voting period for these resolutions is scheduled from February 27 to March 28, 2026.
Key Highlights
Ratification of Aditya Infotech Employee Stock Option Plan 2024 involving equity shares of Re. 1 face value.
Extension of ESOP benefits to eligible employees across Group, Subsidiary, Associate, and Holding companies.
Proposed revision in remuneration for the Chairman, Managing Director, and Whole-Time Director via special resolutions.
Amendment to the Articles of Association (AoA) of the company is also under consideration.
E-voting period set for 30 days, starting February 27, 2026, with results expected by March 31, 2026.
💼 Action for Investors
Investors should examine the explanatory statement for the specific quantum of remuneration increases and the potential equity dilution from the ESOP plan. Ensure that the proposed management compensation is commensurate with the company's financial performance and growth trajectory.
Loading analysis...
CPPLUS Promoters Sell 2% Stake to Comply with Minimum Public Shareholding Norms
Promoters of Aditya Infotech Limited (CPPLUS) have successfully offloaded a 2.00% stake in the company through the open market. This transaction, involving 23,55,961 equity shares, was conducted to meet the mandatory Minimum Public Shareholding (MPS) requirements set by SEBI. The sellers included the Hari Khemka Business Family Trust and Mr. Rishi Khemka. This move ensures the company remains compliant with listing regulations and increases the public float of the stock.
Key Highlights
Total of 23,55,961 equity shares sold, representing 2.00% of the total paid-up equity capital.
Hari Khemka Business Family Trust sold 17,66,971 shares (1.50% stake).
Mr. Rishi Khemka sold 5,88,990 shares (0.50% stake).
The sale was executed via the open market route specifically for MPS compliance under SEBI regulations.
The transaction was completed within the stipulated timeline as per the company's previous intimation.
💼 Action for Investors
This is a routine regulatory compliance event and should not be viewed as a negative signal regarding the company's fundamentals. Investors can expect slightly improved liquidity in the counter due to the increased public float.
Loading analysis...
Aditya Infotech Promoters to Sell Up to 2% Stake for MPS Compliance
Promoters of Aditya Infotech (CPPLUS), including Hari Khemka Business Family Trust and Mr. Rishi Khemka, have announced their intention to sell up to 2% of the company's equity. The sale involves 23,55,961 shares and is scheduled to take place between February 25, 2026, and March 05, 2026. This divestment is specifically aimed at meeting SEBI's Minimum Public Shareholding (MPS) requirement, as the current promoter holding stands at 76.74%. The transaction will be conducted through the open market to increase the public float to the mandatory 25%.
Key Highlights
Promoters to divest up to 2% stake, equivalent to 23,55,961 equity shares.
Current promoter and promoter group shareholding is 76.74%, exceeding the 75% limit.
Divestment window is set from February 25, 2026, to March 05, 2026.
Purpose of the sale is to comply with SEBI Minimum Public Shareholding (MPS) norms.
Promoter group has undertaken not to purchase any shares on the days of the sale.
💼 Action for Investors
Investors should anticipate potential short-term price volatility due to the increased supply of shares in the open market. However, this is a routine regulatory requirement that will improve the stock's liquidity over the long term.
Loading analysis...
Prakash Pipes Acquires 26% Stake in BECIS Solar 3 for Captive Power Project
Prakash Pipes Limited has completed the acquisition of a 26% equity stake in BECIS Solar 3 Private Limited for a total investment of ₹3,58,379. The company was allotted 3,51,352 equity shares at a price of ₹1.02 per share, including a small premium. This strategic investment is intended to develop a solar power project to supply captive power to the company's operations. The move complies with the Electricity Rules, 2005, and aims to reduce long-term energy costs.
Key Highlights
Acquired 26% equity share capital of BECIS Solar 3 Private Limited
Total investment of ₹3,58,379 for 3,51,352 fully paid-up equity shares
Shares issued at face value of ₹1 each with a premium of ₹0.02 per share
Investment aimed at developing a solar power project for captive power supply
Move aligns with Electricity Rules, 2005 for operational cost optimization
💼 Action for Investors
While the financial outlay is small, this is a positive step toward energy self-sufficiency and ESG compliance. Investors should view this as a long-term cost-saving measure for the company's manufacturing operations.
Loading analysis...
CP PLUS (Aditya Infotech) Secures Title Sponsorship for Punjab Kings in IPL 2026
Aditya Infotech Limited (CPPLUS) has announced its role as the Title Sponsor for the Punjab Kings IPL franchise for the 2026 season. This high-profile partnership is designed to boost brand visibility and consumer engagement across India through digital campaigns and stadium activations. The company aims to leverage the IPL's massive reach to reinforce its leadership in the security and surveillance sector. While the financial outlay for the sponsorship was not disclosed, it marks a significant step in the company's brand-building strategy.
Key Highlights
CP PLUS named Title Sponsor for Punjab Kings for the upcoming IPL 2026 season.
Partnership includes digital-first storytelling and immersive fan-focused experiences.
Strategic move to engage a nationwide audience and promote 'Make in India' security solutions.
CP PLUS operates the largest integrated manufacturing facility for security products in Kadapa, Andhra Pradesh.
💼 Action for Investors
Monitor the company's marketing expenditure and its impact on operating margins in the 2026 fiscal year. Assess if the increased brand visibility translates into higher market share in the retail security segment.
Loading analysis...
Prakash Pipes Receives ₹75 Crore Loan Repayment from Promoter Entity Prakash Industries
Prakash Pipes Limited (PPL) has announced the successful recovery of a ₹75 crore loan from its promoter group entity, Prakash Industries Limited. The loan was originally extended as a related-party transaction on an arm's length basis and had received all necessary regulatory and board approvals. This repayment significantly enhances PPL's cash position and reduces the risk associated with related-party receivables. Such a move is generally viewed as a positive signal for corporate governance and balance sheet strength.
Key Highlights
Full repayment of ₹75 crore loan by promoter group entity Prakash Industries Limited
Transaction conducted on an arm's length basis and in the ordinary course of business
Repayment improves the company's liquidity and reduces related-party financial exposure
Compliance with SEBI (LODR) Regulation 23 and 30 confirmed by the company
💼 Action for Investors
Investors should view this as a positive development that de-risks the balance sheet. Monitor how the company utilizes this ₹75 crore cash inflow for future growth or debt reduction.
Loading analysis...
Aditya Infotech Q3 FY26: Revenue up 37%, PAT jumps 139% with strong FY27 guidance
Aditya Infotech (CPPLUS) reported a robust Q3 FY26 with revenue growing 37.3% YoY to ₹1,139.1 crores and adjusted PAT surging 138.8% to ₹96 crores. EBITDA margins expanded significantly by 391 bps to 12.6%, driven by a favorable product mix and higher localization. Management has raised its FY26 revenue guidance to ₹3,900-₹4,100 crores and provided a bullish FY27 outlook with revenue targets of ₹5,350-₹5,550 crores. Strategic initiatives include a partnership with Qualcomm for AI solutions and the launch of new mass-market brands EYRA and NEXIVUE.
Key Highlights
Q3 Revenue grew 37.3% YoY to ₹1,139.1 Cr; EBITDA surged 98.7% to ₹144.6 Cr.
EBITDA margins improved by 391 bps to 12.6% due to higher localization and brand mix.
Market share reached over 39% as of Q2 FY26, with CP PLUS brand contributing 87% of revenue.
Management guided for 30-35% revenue growth in FY27, targeting up to ₹5,550 Cr with PAT margins of 7.5%-8.5%.
Manufacturing capacity expanded to 1.9 million units/month, with a target of 2.1 million by Q4 FY26.
💼 Action for Investors
Investors should focus on the company's successful margin expansion and aggressive growth guidance for FY27. The shift towards high-margin AI-led solutions and backward integration through new plants in Andhra Pradesh are key long-term value drivers to monitor.
Loading analysis...
Prakash Pipes Q3 FY26: Net Profit at ₹10 Cr, Sales at ₹181 Cr with Strong Volume Growth
Prakash Pipes Limited reported a Net Profit of ₹10 Crores on Net Sales of ₹181 Crores for the quarter ended December 31, 2025. For the nine-month period, the company achieved a Net Profit of ₹30 Crores with an EPS of ₹12.45. The PVC Pipes division saw volume growth to 11,068 MT, benefiting from stabilized resin prices and strong demand in housing and infrastructure. The Flexible Packaging division also grew its volume to 4,329 MT, supported by capacity expansion and a wider product range.
Key Highlights
Quarterly Net Sales reached ₹181 Crores with an EBITDA of ₹18 Crores.
Net Profit for the nine months ended Dec 2025 stood at ₹30 Crores with an EPS of ₹12.45.
PVC Pipes & Fittings sales volume increased to 11,068 MT from 10,547 MT in the previous year's quarter.
Flexible Packaging division volume grew to 4,329 MT compared to 4,015 MT YoY.
Management indicates that the downward trend in PVC Resin prices has been arrested, supporting business normalcy.
💼 Action for Investors
Investors should monitor the sustainability of volume growth in the PVC segment as resin prices stabilize. The company's expansion in the flexible packaging division provides a diversified revenue stream worth watching.
Loading analysis...
Prakash Pipes Q3 FY26 Net Profit Drops 56% YoY to ₹10.11 Crore
Prakash Pipes Limited reported a significant decline in its financial performance for Q3 FY26, with Net Profit falling 56.2% YoY to ₹10.11 crore. Total revenue from operations decreased by 5.9% YoY to ₹181.15 crore, primarily due to lower realizations despite a growth in sales volumes. The PVC Pipes and Flexible Packaging segments both saw volume growth of 4.9% and 7.8% respectively, but segment margins were heavily compressed. Management remains optimistic about future demand recovery driven by housing, agriculture, and infrastructure sectors.
Key Highlights
Net Profit for Q3 FY26 stood at ₹10.11 crore, a sharp decline from ₹23.11 crore in Q3 FY25.
Revenue from operations fell to ₹181.15 crore compared to ₹192.50 crore in the same period last year.
PVC Pipe sales volume increased to 11,068 MT from 10,547 MT YoY, showing resilient demand despite price volatility.
Flexible Packaging segment profit contracted significantly to ₹1.91 crore from ₹12.80 crore YoY.
Earnings Per Share (EPS) for the quarter dropped to ₹4.23 from ₹9.66 in the previous year's corresponding quarter.
💼 Action for Investors
Investors should exercise caution as the company is facing severe margin pressure despite maintaining volume growth. The stock may face short-term pressure until PVC resin prices stabilize and profitability margins show signs of recovery.